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Abstract 
Objective: Palatable food disrupts normal appetite regulation, which may contribute to the 
etiology of obesity.  Neuropeptide Y (NPY) and cholecystokinin play critical roles in the 
regulation of food intake and energy homeostasis, while adiponectin and carnitine palmitoyl-
transferase (CPT) are important for insulin sensitivity and fatty acid oxidation. This study 5 
examined the impact of short and long term consumption of palatable-high-fat-diet (HFD) on 
these critical metabolic regulators. 
Methods: Male C57BL/6 mice were exposed to laboratory chow (12% fat), or cafeteria-style 
palatable-HFD (32% fat) for 2 or 10 weeks. Body weight and food intake were monitored 
throughout. Plasma leptin, hypothalamic NPY and cholecystokinin, and mRNA expression of 10 
leptin, adiponectin, their receptors, and CPT-1, in fat and muscles were measured.  
Results: Caloric intake of the palatable-HFD group was 2-3 times greater than control, 
resulting in a 37% higher body weight. Fat mass was already increased at 2 weeks; plasma 
leptin concentrations were 2.4 and 9 times higher than control at 2 and 10 weeks respectively. 
Plasma adiponectin was increased at 10 weeks. Muscle adiponectin receptor1 was increased 15 
at 2 weeks, while CPT-1 mRNA was markedly upregulated by HFD at both time points. 
Hypothalamic NPY and cholecystokinin content were significantly decreased at 10 weeks.  
Conclusion: Palatable-HFD induced hyperphagia, fat accumulation, increased adiponectin, 
leptin, and muscle fatty acid oxidation, and reduced hypothalamic NPY and cholecystokinin. 
Our data suggest that the adaptive changes in hypothalamic NPY and muscle fatty acid 20 
oxidation are insufficient to reverse the progress of obesity and metabolic consequences 
induced by a palatable-HFD. 
Key words: hyperphagia, adiponectin, adiponectin receptor 1, CPT-1, leptin receptor 
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Introduction 
The increasing prevalence of overweight and obesity has become a crucial worldwide health 
problem. The epidemic of obesity on an unchanging genetic background suggests powerful 
environmental forces can affect energy balance. Throughout evolution our concern was with 
food shortages, and our genetic makeup reflects adaptive responses set in train to ensure 5 
survival 1. Starvation and famine exerted a strong selection effect on the human genome, 
whereby adaptations that selected to promote fat deposition in times of plenty had a survival 
advantage in periods of food shortage and famine, a concept that has been coined the “thrifty-
genotype” 1.  One of the major public health concerns in this century is the medical 
consequences stemming from the ready availability of high-fat, energy-dense foods, as this is 10 
one of the fundamental causes of the obesity epidemic 2. Physiological experiments illustrate 
that energy-dense diets can potentially compromise normal appetite regulation in humans 3. 
This study aimed to specifically explore the impact of palatable foods on appetite and 
metabolic regulation. 
 15 
There has been a substantial increase in knowledge of the neural regulatory systems involved 
in regulating appetite and energy balance, specifically in the hypothalamus that responds to 
nutritional signals and plasma hormones, such as leptin and insulin, enabling accurate 
regulation of food intake and body weight 4. The roles of orexigenic neuropeptides, including 
neuropeptide Y (NPY) and agouti-related protein, and anorexigenic peptides, including 20 
melanocyte-stimulating hormones and cocaine- and amphetamine-regulated transcript, have 
been widely studied in dietary obese animal models. NPY, a 36 amino acid member of the 
pancreatic polypeptide family, is of interest due to its powerful orexigenic effect 5, and 
critical role in periodic eating behavior and maintenance of body weight 6. Central 
administration of NPY was shown to induce hyperphagia even under conditions of satiation, 25 
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to increase fat deposition, to decrease energy expenditure, and to promote obesity 7, 8. 
However, in addition to these CNS neuropeptides, other peptides may also play a role. 
Cholecystokinin (CCK), which induces satiety by both peripheral and central means, is 
secreted from the duodenal mucosa when ingested fat reaches the duodenum (reviewed in 9). 
CCK is also found in high concentrations in the cortex and hypothalamus 10. Administration 5 
of CCK into the hypothalamus and hindbrain can cause direct anorectic effects 10. Although 
fat is the most potent stimulus for CCK secretion, CCK-induced reduction in food intake and 
gastric emptying are both attenuated in rats maintained on a high-fat diet (HFD) 11. The 
hyperphagic phenotype displayed in CCK2 receptor knockout mice suggests that lack of 
CCK signaling can lead to over consumption 12. However, no study has investigated the 10 
involvement of endogenous central CCK in appetite regulation.   
 
The discovery of proteins produced in the adipose tissue and skeletal muscles that are 
involved in feeding, metabolism, and insulin sensitivity, such as leptin, adiponectin and 
carnitine palmitoyl-transferase (CPT)-1, indicate additional peripheral regulatory systems. 15 
Circulating leptin, as well as insulin, directly access the arcuate nucleus (Arc) in the 
hypothalamus to inhibit neurons expressing orexigenic peptides and activate neurons 
expressing anorexigenic peptides 4. Diabetes, obesity, and the metabolic syndrome 
susceptibility locus have been mapped to chromosome 3q27. This region encodes adiponectin, 
a 30KDa protein secreted exclusively by white adipose tissue (WAT), that is capable of 20 
increasing insulin sensitivity, stimulating fatty acid oxidation, and inhibiting the vascular 
inflammatory process 13, 14. Skeletal muscle plays an important role in the clearance of blood 
free fatty acids and triglyceride, and in whole-body fatty acid oxidation, and CPT is the rate-
limiting step for fatty acid oxidation and ketogenesis 15. Dysregulation of these cytokines can 
accelerate the process of fat accumulation and glucose intolerance 16-19.  25 
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Consumption of palatable food disrupts normal appetite regulation. Over-eating is stimulated 
by the ready availability of food rich in fat and sugar 20. Thus the aim of this study is to look 
at appetite regulation under palatable HFD and the contribution of central and peripheral 
metabolic mediators. The hypothesis is that animals will display marked over-consumption in 5 
the face of a palatable HFD, and this will be associated with a decrease in the putative satiety 
factors and an increase in the appetite stimulant NPY. We also hypothesized that uncontrolled 
fat accumulation in dietary obesity is related to dysregulation of peripheral leptin, adiponectin, 
their receptors, and CPT-1. As adaptive changes in response to palatable HFD are developed 
over time 21, 22, we aimed to examine both short term and long term effects.  10 
 
Materials and methods 
1. Dietary intervention 
Animals were housed at 20 ± 2°C in micro-isolator cages with 8 in each, and maintained on a 
12:12 h light/dark cycle (lights on at 06:00h). Male C57BL/6 mice (aged 5 weeks, n = 60) 15 
were assigned to four groups of equal average body weight. The control groups were exposed 
to standard laboratory chow (GlenForrest stockfeeders, Perth, Australia) which provided 3.54 
kcal/g of diet (12% energy as fat), while the palatable HFD fed groups (HFD group) were 
presented with HFD providing 4.23 kcal/g of diet (32% energy as fat), for a period of 2 or 10 
weeks. Briefly, the HFD consists of modified laboratory chow made on-site by combining, as 20 
a percent of total weight, 60% powdered chow, 33% sweetened condensed milk, and 7% 
saturated animal fat. The high-fat modified chow was supplemented with highly palatable 
cafeteria style food such as cakes and biscuits (4-5 different food types per day) of known 
caloric content. Body weight was measured between 16:00 and 17:00 h twice a week. Fresh 
food was provided daily. For the measurement of caloric intake, preweighed food was put 25 
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inside a container into a clean cage and the remainder collected 24 hours later. The current 
study was approved by the Animal Experimentation Ethics Committee of the University of 
Melbourne. 
 
2. Sample collection 5 
Animals were given ad libitum access to food before dissection. At the end of the experiment, 
mice were deeply anesthetized (ketamine/xylazine 180/32 mg/kg, intraperitoneal). After 
measurement of naso-anal (N-A) length and girth (waist and groin circumferences), blood 
was collected by cardiac puncture and separated plasma was stored at -80°C for hormone 
measurements. Mice were killed by decapitation and the brain was rapidly dissected on ice 10 
into regions containing paraventricular nucleus (PVN), Arc, anterior and posterior 
hypothalamus (AH and PH), and medulla. Brain regions were weighed, frozen on dry ice, and 
stored at -80°C for determination of NPY and CCK peptide content. Body fat (testicular WAT, 
retroperitoneal (Rp) WAT, leg subcutaneous WAT, visceral WAT, and brown adipose tissue 
(BAT)) was collected as well as various organs (heart and liver) and skeletal muscles 15 
(mixture of adductor magnus, gracillis posticus, semimembranosus) to provide further 
markers of growth and metabolism. Tibia length was measured. 
 
3. Assays 
3.1 Brain NPY, plasma NPY, leptin, and adiponectin assays 20 
Endogenous NPY from the various brain regions was extracted by 0.5M acetic acid, 
lyophilized and reconstituted with assay buffer. NPY-like immunoreactivity was measured by 
a specific radioimmunoassay using synthetic NPY as standard (10-1280 pg/tube, Auspep, 
Australia) as described before 23. NPY in each brain region was calculated as pmol NPY per 
mg tissue. Plasma leptin and adiponectin concentrations were measured using commercially 25 
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available radioimmunoassay kits (Linco, Missouri, USA), according to the manufacturers’ 
instructions. 
 
3.2 Brain CCK assay 
CCK-like immunoreactivity in the various brain regions was measured by a specific 5 
radioimmunoassay using synthetic sulphated CCK-8 as standard (0.2-200 fmol/tube) 24. 
Briefly, acid extracts from the 10 week diet cohort were dehydrated and reconstituted in water. 
Samples were incubated with antiserum 92128 (1:60,000, a generous donation by Jens 
Rehfeld, University Hospital, Copenhagen, Denmark) and 125I-Bolton-Hunter-CCK-8 
(Amersham International, Bucks, UK). CCK in each brain region was calculated as fmol 10 
CCK per mg tissue. 
 
4. Real-time PCR 
Total RNA was isolated from 10 mg of both skeletal muscle and WAT using ToTALLY 
RNATM kit (Ambion Inc., Austin, USA) protocol and reagents. Total RNA concentration was 15 
determined spectrophotometrically at 260 and 280 nm. RNA was reverse transcribed to 
synthesize first strand cDNA using AMV reverse transcriptase (Promega, Madison, WI). The 
cDNA was stored at -20°C for subsequent analysis 25. Primers (Table 1) were purchased from 
GeneWorks (Adelaide, Australia). Real-time PCR was performed using the GeneAmp® 5700 
Sequence Detection System (Applied Biosystems). The expression of the gene of interest 20 
(adiponectin, adiponectin receptor (AdipoR)1, leptin, leptin receptor, CPT-1 was standardized 
to rat cyclophilin. 
 
5. Statistical analyses 
Results are expressed as mean ± S.E.M. Body weight of HFD and chow fed mice, and 24h 25 
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food intake, were analyzed using ANOVA with repeated measures, followed by a post hoc 
LSD test. Differences in fat and organ masses, plasma hormone concentrations, brain NPY 
and CCK concentrations and content, and mRNA expression were analyzed using Student’s 
unpaired t-test.   
 5 
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Results 
Effects of palatable HFD on energy intake and body weight 
Prior to the introduction of the palatable HFD, no difference in energy intake or body weight 
was observed between the two groups. Caloric intake was almost doubled during the first 24h 
of HFD feeding, and this was progressively increased to nearly 3 times within the first 5 days 5 
of dietary intervention (p< 0.05 for all time points, Fig 1A). Thereafter, the hyperphagic state 
of the HFD group was maintained throughout the experimental period (p< 0.05 for all time 
points, Fig 1A).  
 
The average body weight of the HFD group began to increase more rapidly than chow fed 10 
animals shortly after the diet began, and was significantly higher than the chow fed group 
after 3 days of diet (Fig 1B, p< 0.05). Over time, this difference became more pronounced 
(Fig 1B). After 2 weeks of HFD, the average weight gain was 40% greater than the control 
mice (∆BW 7.7 ± 0.3 g in the HFD group vs. 5.4 ± 0.3 g in the control group, p< 0.05). After 
10 weeks of diet, the average weight gain of the HFD group (∆BW 22.3 ± 0.5 g) was 86% 15 
more than the control group (∆BW 12.0 ± 0.5 g, p< 0.05).  
 
Effects of palatable HFD on body size, organ and fat masses 
Both N-A length and girth (waist and groin circumferences) were significantly increased by 
HFD at 10 weeks, while tibia length was not changed (Table 2). Liver, heart, and BAT 20 
weights were only significantly increased at 10 weeks (Table 2). After 2 weeks of dietary 
intervention, in addition to testicular and leg subcutaneous WAT, RpWAT mass was also 
markedly increased by nearly 80% when data were considered as net mass, or more than 60% 
when standardized as a percentage of body weight. The sum of WAT masses sampled (Sum) 
of the HFD fed mice was increased by 53% (p< 0.001).  After the longer period of diet 25 
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intervention, the increase in both BAT and WAT mass of all locations sampled was more 
pronounced, with total WAT mass sampled more than four times greater than control mice 
(p< 0.001, Table 2).  
 
Effects of palatable HFD on plasma hormones 5 
After 2 weeks of HFD, plasma leptin concentration was more than doubled in the mice fed a 
HFD compared to the mice on the control diet (p< 0.05); furthermore, with an additional 8 
weeks of HFD, plasma leptin concentration was 9 times greater than in control mice (p< 0.05, 
Table 3). Plasma leptin concentration was positively correlated with RpWAT mass at both 2 
weeks (p< 0.0001, r = 0.77, n = 30), and 10 weeks (p< 0.0001, r = 0.96, n = 30). Plasma NPY 10 
concentration was increased by HFD, with a more marked effect at 10 weeks (50% increase) 
than 2 weeks (25% increase) (p< 0.05, at both time points, Table 3). After two week diet, no 
difference in plasma adiponectin levels was observed between chow and HFD fed mice 
(Table 3). However at 10 weeks, plasma adiponectin concentration was increased by 24% in 
the HFD fed mice compared with the control animals (p< 0.05, Table 3).  15 
 
Effects of palatable HFD on brain NPY and CCK peptides 
No difference in NPY concentration in hypothalamic subregions was observed at 2 weeks 
(data not shown), and the total hypothalamic NPY content was also similar in both groups 
(14.9 ± 0.3 vs. 15.2 ± 0.4 pmol in HFD and control groups, respectively). However, in the 20 
longer term, a significant reduction in NPY concentrations in the AH, Arc and PH was 
observed in HFD fed animals (p< 0.05, Fig 2). Total hypothalamic NPY content was 
significantly reduced to 10.3 ± 0.5 pmol compared with 13.8 ± 0.6 pmol in control mice (p< 
0.05). 
 25 
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At 10 weeks, CCK concentrations in the AH, Arc, PH and medulla were significantly 
decreased by 16%, 15%, 22% and 15% respectively in the HFD group (p< 0.05, Fig 3). No 
obvious change was observed in the PVN between the two dietary groups. The total 
hypothalamic CCK content was also lower in the animals fed a HFD (347.5 ± 18.3 fmol) 
compared with control animals (446.4 ± 25.7 fmol, p< 0.05). 5 
 
Effects of palatable HFD on gene expression in skeletal muscle and WAT 
In skeletal muscle, AdipoR1 expression was only upregulated after 2 weeks of diet (p< 0.05, 
Fig 4A). The mRNA expression of the leptin receptor was significantly reduced in the HFD 
group at 10 weeks (p< 0.05, Fig 4B). CPT-1 mRNA expression was significantly increased at 10 
both 2 and 10 weeks (p< 0.05, Fig 4C).  
 
In WAT, no obvious changes in adiponectin mRNA expression were observed at 2 and 10 
weeks (Fig 5A). WAT leptin mRNA expression was increased by 8 fold after 10 weeks of 
HFD (p< 0.05, Fig 6B), while its receptor expression in WAT was reduced by 40% and 71% 15 
at 2 and 10 weeks respectively by HFD (p< 0.05, Fig 5C). There was a negative correlation 
between the expression of leptin and leptinR mRNA in WAT at 10 weeks (P< 0.05, r = 0.50, n 
= 24). WAT CPT-1 mRNA expression was only significantly increased at 2 weeks (p< 0.05), 
and tended to decrease at 10 weeks (P = 0.09, Fig 5D). There was no significant change in 
mRNA expression of the house keeping gene cyclophilin in skeletal muscle and WAT at 20 
either 2 or 10 weeks. 
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Discussion 
In this study, obesity was induced in mice by using a palatable cafeteria-style HFD, which 
was accompanied with markedly increased fat accumulation. An important observation in the 
current study is that the counter-regulatory mechanisms apparently set in train by sustained 
overfeeding, increased leptin and reduced hypothalamic NPY, failed to impact on appetite. 5 
The reduced endogenous CCK observed in the hypothalamus may have contributed to the 
hyperphagia. Mice exposed to our palatable diet appeared to gain more weight than animals 
of the same age and strain given non-cafeteria diet with even higher fat composition (59-60% 
from fat 26-29), suggesting a greater response to the palatable HFD, possibly related to 
hedonic-type eating. 10 
 
The energy dense diet used here was of a different nature from pelleted HFDs. Exposure to 
this diet caused an immediate and sustained increase in caloric intake, and a significant 
increase in body weight within 3 days of diet inception. The weight gain appeared to 
accelerate after 6 weeks, possibly due to decreased energy expenditure relative to increased 15 
energy intake as shown by Ghibaudi and colleagues 30. Overconsumption of palatable food 
gradually shifts the set point for energy balance and body weight, similar to the adaptation 
observed in drug addiction 31, 32. This change in energy balance set point may explain the 
prolonged hyperphagia. The increase in percentage WAT mass induced by HFD suggests 
adipose accumulation largely contributed to the weight gain. In addition, we postulated that 20 
the increased liver weight might be mainly due to lipid deposit, as liver is the systemic buffer, 
largely increasing its lipid content to help avoid an excessive increase in circulating lipids.  
 
Feeding is not only controlled by homeostatic mechanisms which theoretically would allow 
an individual to maintain an ideal body weight but also by a brain reward system 33. Palatable 25 
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food activates the reward system, to reinforce motives without homeostatic value 20. 
 
A number of Arc NPY neurons express the “long” isoform of the leptin receptor, and these 
cells respond to alterations in circulating leptin levels, thus regulating the synthesis and 
release of NPY 34-36. Although leptin resistance was reported in obesity 37, reduced Arc NPY 5 
content in our mice at 10 weeks may represent a possible response to the hyperleptinemia. 
The decreased NPY concentrations in the AH and PH may reflect a decrease in NPY release 
from the Arc. This is supported by our previous study, in which baseline NPY release was 
reduced by long term exposure to palatable HFD in rats 38. Although NPY was not changed in 
the PVN, changes in the AH and the PH would still affect feeding behavior.  10 
 
In contrast to the reduction in Arc NPY peptides observed here in the face of chronic obesity, 
increased Arc NPY mRNA was observed in dietary obese prone rats 39, and the activity of 
hypothalamic neurons expressing NPY is greatly elevated in ob/ob mice that are morbidly 
obese because of their inability to produce leptin 35, 40. Fasting or chronic food restriction 15 
increases NPY mRNA expression, and refeeding restores it. Both increases and decreases in 
brain NPY have been observed in previous short and long term studies using pelleted HFD 27, 
41-43
. Similarly the contribution of NPY to palatable diet induced obesity remains unclear. We 
previously observed a gradual downregulation of hypothalamic NPY over the development of 
dietary obesity in Sprague Dawley rats using the same diet 21, 38, a similar pattern observed in  20 
the present study with C57BL/6 mice. Interestingly, changes in weight gain, caloric intake, 
and hypothalamic NPY peptide were greater in mice than in rats 21, 38.  
 
The previously reported transient increase in hypothalamic NPY expression in pre-obese 
Otsuka Long Evans Tokushima Fatty rat suggests that there may be a threshold for NPY to 25 
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initiate hyperphagia, but NPY is not necessary to maintain the hyperphagic state 44. One 
interpretation of our result is that the positive energy balance and satiety due to HFD, reduced 
NPY synthesis in the Arc and therefore whole hypothalamic NPY content. Perhaps this 
suggests an attempt to restrain overconsumption of palatable food. The altered NPY 
production may modulate NPY receptor expression, as increased hypothalamic Y2 and Y5 5 
receptor expression was observed in dietary obese rodents 43, 45. In keeping with this, we have 
previously found exaggerated responses to exogenous NPY administration in dietary induced 
obese rats 38. Furthermore, previously we observed a reduced PVN alpha-melanocyte-
stimulating hormone (α-MSH), together with reduced NPY peptide, after chronic high fat 
feeding in the rat 21 which may explain the prolonged hyperphagia. Chronic hyperphagia and 10 
obesity may alter the balance of hypothalamic peptidergic systems controlling feeding.  
 
The current study demonstrated for the first time that long term palatable HFD downregulates 
central CCK content. CCK, a satiety signal released from the intestine after ingestion of 
nutrients, leads to meal termination 9, 46. However locally generated hypothalamic CCK may 15 
also have a role, since direct injection of CCK into this area can alter food intake 10. Although 
reduced CCK in the cortex and increased hypothalamic CCK receptor and binding were 
found during fasting 47, the changes induced by prolonged hyperphagia have not been 
previously studied. Decreased brain CCK was found in the cerebral cortex but not in the 
hypothalamus of ob/ob mice 48, 49. Our data suggest that the inhibition imposed by CCK on 20 
the hypothalamic feeding circuitry might be attenuated, and this may contribute to the 
sustained hyperphagia; however confirmation of this proposal would require further work. 
Our findings taken together with the observation that high-fat diets attenuate the inhibitory 
effect of exogenous CCK 11 suggest a loss of both peripheral and central satiety effects of 
CCK. 25 
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In the periphery, NPY is released from the sympathetic nerves and the adrenal medulla, by 
intense or prolonged sympathetic activation 50-53. The persistent increase in plasma NPY 
levels in HFD fed mice reported in this study may represent hyperactivity of the sympathetic 
nervous system. There is also evidence of increased sympathetic activity in obese humans 54-5 
56
. Since NPY has potential angiogenic functions and stimulates cardiac hypertrophy 51, the 
increase in circulating NPY if sustained, may lead to changes in blood pressure or vascular 
function.  
 
It has been recognized that decreased plasma adiponectin concentrations is linked to both 10 
animal and human obesity, which is thought to largely contribute to the insulin resistance, 
vascular dysfunction, and atherosclerosis that often accompany obesity 13. Interestingly, in 
the current study plasma adiponectin level was significantly increased at 10 weeks by HFD 
without an obvious change in adipose adiponectin mRNA expression. While most reports 
suggested adiponectin concentration was reduced in human obesity, increased adiponectin 15 
has been observed in morbidly obese individuals, and attributed to disturbed endocrine loops 
57
. In addition, postprandial hypertriglyceridemia and hyperglycemia may mediate the 
increased adiponectin levels as shown in obese but not lean subjects 58. The mice in the 
current study were not fasted before harvest, which could explain increased adiponectin 
levels at 10 weeks. Increased plasma adiponectin has also been observed in Sprague Dawley 20 
rats after 12 weeks of HFD in our laboratory 59. 
 
In skeletal muscle, adiponectin plays a key role in insulin sensitivity, glucose utilization, and 
fatty acid oxidation 60-62. The action of adiponectin on skeletal muscle was found to be 
blunted in obesity, which may contribute to reduced adiponectin sensitivity and eventually 25 
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insulin resistance 62, 63. Two adiponectin receptors, AdipoR1 and AdipoR2, have been 
identified recently 64. Fasting increased the expression of muscle AdipoR1 to increase fatty 
acid oxidation, which was restored to baseline after refeeding 65. In the current study, an early 
increase in AdipoR1 might be a compensatory reaction to increase glucose uptake and lipid 
oxidation in the skeletal muscle.  5 
 
Skeletal muscle is an important contributor to whole-body energy expenditure, and has a key 
role in determining systemic insulin sensitivity due to major proportion of glucose utilization, 
including redirecting spared glucose towards de novo lipogenesis in adipose tissue, occurring 
in skeletal muscle under insulin-stimulated conditions 66. Any reduction of metabolic rate in 10 
muscle would reduce glucose utilization, thereby leading to hyperinsulinaemia. The reduced 
leptinR mRNA expression observed in both skeletal muscle and WAT is likely a physiological 
response to the increased leptin production. Leptin may increase glucose uptake by an 
insulin-independent mechanism in skeletal muscle 67, and stimulate fatty acid oxidation in 
both adipocyte and muscle, via signalling pathways involving phosphatidylinositol 3 kinase 15 
and AMP-activated protein kinase, which can be inhibited by a CPT-1 inhibitor 66. Therefore, 
the reduction in leptinR mRNA expression in both adipose tissue and skeletal muscle might 
impair glucose uptake and fatty acid oxidation in these organs.  
 
Increased fatty acids in obese individuals can blunt the ability of muscle to oxidize fat which 20 
is thought to be related to the pathogenesis of insulin resistance 68, 69. In the fed state when 
insulin is elevated and glucagon levels are low, CPT-1 activity is inhibited to increase fatty 
acid synthesis; while in the catabolic state, CPT-1 is activated to stimulate fatty acid oxidation 
15
. The increased CPT-1 mRNA expression in muscle at both 2 and 10 weeks suggests the 
catabolic activity was higher in obese animals to reduce the excessive adipose store. However, 25 
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in WAT CPT-1 mRNA expression was only increased in the short term, suggesting impaired 
function in adipose tissue after long term hypertrophy, which could not be compensated by 
increased CPT-1 mRNA in skeletal muscle. We speculate that, in the obese state, particularly 
in the long term, the fat cells act more as a place to store excessive triglycerides, and lose 
their ability to maintain homeostasis; while the contribution of skeletal muscles to fatty acid 5 
oxidation and glucose metabolism might increase. However, the compensation is not 
sufficient.  
 
In conclusion, obesity was readily induced by a palatable high-fat western cafeteria diet in 
mice with a sustained doubling of caloric intake. The hyperleptinemia was accompanied by 10 
reduced leptinR mRNA in both muscle and adipose tissue. Moreover, with excessive fat 
accumulation and hyperleptinemia, fatty acid oxidation was upregulated, and the orexigenic 
peptide NPY was downregulated, modest reduction in of the CCK peptide was observed in 
the hypothalamus. However our data suggest that these adaptive changes in the hypothalamic 
neuropeptide system and fatty acid oxidation pathway are not sufficient to correct the 15 
excessive caloric intake and fat accumulation.  
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Titles and legends to figures 
Fig 1 Energy intake (A) and body weight (B) of chow ( n=15) and HFD ( n=15) fed mice 
during the experimental period. Results are expressed as mean ± S.E.M. Energy intake were 
analysed by Student’s unpaired t test. Body weight were analysed by ANOVA with repeated 
measures followed by a LSD post hoc test. 5 
* Significantly different from chow fed mice (p<0.05). 
 
Fig 2 NPY-like immunoreactivity in chow ( n = 15) or HFD ( n = 15) fed mice at 10 
weeks. Areas shown are the anterior hypothalamus (AH), paraventricular nucleus (PVN), 
arcuate nucleus (Arc), posterior hypothalamus (PH) and medulla (Med). Results are 10 
expressed as mean ± S.E.M. Data were analysed by Student’s unpaired t test.  
* Significantly different from chow fed mice (p< 0.05). 
 
Fig 3 CCK-like immunoreactivity in chow ( n = 15) or HFD ( n = 15) fed mice at 10 
weeks. Areas shown are the anterior hypothalamus (AH), paraventricular nucleus (PVN), 15 
arcuate nucleus (Arc), posterior hypothalamus (PH) and medulla (Med). Results are 
expressed as mean ± S.E.M. Data were analysed by Student’s unpaired t test.  
* Significantly different from chow fed mice (p< 0.05). 
 
Fig 4 mRNA expression of AdipoR1 (A), leptin receptor (B), and CPT-1 (C) in skeletal 20 
muscle of chow ( n = 12) or HFD ( n = 10) fed mice at 2 and 10 weeks. Data are 
expressed as mean ± S.E.M; results are relative to cyclophilin. Data were analysed by 
Student’s unpaired t test.  
* Significantly different from chow fed mice (p< 0.05). 
 25 
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Fig 5 mRNA expression of adiponectin (A), leptin (B), leptin receptor (C), and CPT-1 (D) in 
WAT of chow ( n = 12) or HFD ( n = 10) fed mice at 2 and 10 weeks. Data are expressed 
as mean ± S.E.M; results are relative to cyclophilin. Data were analysed by Student’s 
unpaired t test.  
* Significantly different from chow fed mice (p< 0.05). 5 
Table 1 Primer used for real-time PCR  
Gene 
GenBank 
Accession 
No. 
Forward Primer (5' → 3') Concentration (mM) Reverse Primer (5' → 3') 
Conccentration 
(mM) 
Adiponectin NM_009605 TCCTGGAGAGAAGGGAGAGAAAG 9 CAGCTCCTGTCATTCCAACATC 9 
Adiponectin 
receptor 1 NM_028320 GACTGGCAACATCTGGACACAT 3 ATATTTGGTCTCAGCATCGTCAAG 3 
CPT-1 AF029875.1 CCTTGGCTACTTGGAACGAATTCT 3 GCGCATGCAGTGGGACAT 3 
Cyclophilin M19533 CTGATGGCGAGCCCTTG 4 TCTGCTGTCTTTGGAACTTTGTC 4 
Leptin NM_008493 TCTATTGCATTTACATACCGCATTTC 3 TTATTTTTACGACCCCAGGTATCC 3 
Leptin 
receptor NM_010704 GCAGTCCAGCCTATACGCTTGT 3 TAGTAACGTCCCCATCCATTTTTC 3 
 
CPT-1: carnitine palmitoyl-transferase-1. 
 
 5 
Table 2 Effect of 2 weeks and 10 weeks of HFD on body weight, length, girth, organ mass, 
and adiposity 
2 weeks 10 weeks 
 Control HFD Control HFD 
 
(n=15) (n=15) (n=15) (n=15) 
     
Body weight (g) 22.1 ± 0.3 23.5 ± 0.3* 27.2 ± 0.4 37.9 ± 0.7* 
N-A Length (cm) 8.8 ± 0.1 8.7 ± 0.1 9.4 ± 0.1 9.9 ± 0.1* 
Waist (cm) 8.8 ± 0.1 8.7 ± 0.1 7.5 ± 0.1 8.9 ± 0.1* 
Groin (cm) 7.5 ± 0.1 7.6 ± 0.1 7.9 ± 0.1 9.4 ± 0.2* 
Tibia (cm) 2.07 ± 0.03 2.04 ± 0.02 2.03 ± 0.03      2.00 ± 0.03 
Liver (mg) 1140.2 ± 43.3 1101.0 ± 33.4 1318.9 ± 41.0   1773.5 ± 60.6* 
Heart (mg) 123.0 ± 3.7 128.5 ± 2.3 137.3 ± 4.4      159.8 ± 2.8* 
BAT (mg) 54.4 ± 2.9 64.9 ± 4.0 70.1 ± 3.2  192.0 ± 12.4* 
RpWAT (mg) 41.7 ± 2.7 74.0 ± 6.4* 81.3 ± 4.8  453.2 ± 20.3* 
Testicular WAT (mg) 262.1 ± 9.9 470.4 ± 28.8*  446.0 ± 16.3 2161.0 ± 88.4* 
Visceral WAT (mg) 359.6 ± 13.0 399.3 ± 15.8 453.2 ± 9.9 1110.2 ± 61.6* 
Leg WAT (mg) 248.5 ± 15.7 446.9 ± 35.1*   250.8 ± 14.6 1613.8 ± 92.4* 
Sum of WAT (mg) 935.7 ± 35.3 1464.7 ± 82.1*  1392.3 ± 39.3  6186.4 ± 310.8* 
Results are expressed as mean ± S.E.M. Data were analysed by Student’s unpaired t test.  
* Significantly different from control mice of that dietary period (P < 0.05). 
BAT: brown adipose tissue; N-A: naso-anal; Rp: retroperitoneal; WAT: white adipose tissue.5 
  1
Table 3 Plasma leptin, NPY and adiponectin concentrations at 2 and 10 weeks 
2 weeks 10 weeks 
Control HFD Control HFD 
(n=15) (n=15) (n=15) (n=15) 
    
Plasma leptin (ng/ml) 2.3 ± 0.3 5.5 ± 0.6 * 2.9 ± 0.4 26.0 ± 1.6 * 
Plasma NPY (ng/ml) 3.73 ± 0.16 4.67 ± 0.35 * 3.76 ± 0.44 5.58 ± 0.56 * 
Plasma adiponectin (µg/ml) 6.45 ± 0.65 6.02 ± 0.44 5.75 ± 0.48 7.15 ± 0.39 * 
 
Results are expressed as mean ± S.E.M. Data were analysed by Student’s unpaired t test.  
* Significantly different from control mice (P < 0.05). 
HFD: HFD; NPY: neuropeptide Y. 
